Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model

Stem Cells

Volumn 27, Issue 12, 2009, Pages 3063-3073

  Semedo, Patricia ^a   Correa Costa, Matheus ^a   Cenedeze, Marcos Antonio ^a   Malheiros, Denise Maria Avancini Costa ^b   Dos Reis, Marlene Antonia ^c   Shimizu, Maria Heloisa ^b   Seguro, Antonio Carlos ^b   Pacheco Silva, Alvaro ^a,d   Ĉamara, Niels Olsen Saraiva ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Triangulo Mineiro Medical School   (Brazil)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Chronic renal failure; Fibrosis; Ischemia reperfusion injury; Kidney fibrosis; Mesenchymal stem cell

Indexed keywords

CALVASCULIN; COLLAGEN TYPE 1; CREATININE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UREA; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CELL FUNCTION; CELL PROTECTION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FIBROGENESIS; GENE EXPRESSION; GLOMERULOSCLEROSIS; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SRY GENE; URINALYSIS;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NUCLEAR REPROGRAMMING; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 73349083032     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.214     Document Type: Article

References (62)

1. Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come. Am J Kidney Dis 2006;47:375-377.
2. Shah SV, Feehally J. The Third World Kidney Day: looking back and thinking forward. Am J Kidney Dis 2008;51:349-352.
3. Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975;79:95-106.
4. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
5. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996;49:666-678.
6. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
7. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290-301.
8. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases - insights from animal models. Kidney Int 2005;67:404-419.
9. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-2022.
10. Taal MW, Chertow GM, Rennke HG, et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 2001;280:F343-355.
11. Schiller B, Moran J. Focal glomerulosclerosis in the remnant kidney model - an inflammatory disease mediated by cytokines. Nephrol Dial Transplant 1997;12:430-437.
12. Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000;58:1664-1676.
13. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945-955.
14. T̈ogel F, Yang Y, Zhang P, et al. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol 2008;295:F315-F321.
15. Humphreys BD, Duffield JS, Bonventre JV. Renal stem cells in recovery from acute kidney injury. Minerva Urol Nefrol 2006;58:329-337.
16. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 2008;59:311-325.
17. Duffield JS, Bonventre JV. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int 2005;68:1956-1961.
18. Semedo P, Wang PM, Andreucci TH, et al. Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. Transplant Proc 2007;39:421-423.
19. Semedo P, Palasio CG, Oliveira CD, et al. Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int Immunopharmacol 2009;9:677-682.
20. T̈ogel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007;292:F1626-F1635.
21. Lin WR, Brittan M, Alison MR. The role of bone marrow-derived cells in fibrosis. Cells Tissues Organs 2008;188:178-188.
22. Perez-Ruiz L, Ros-Lopez S, Cardus A, et al. A forgotten method to induce experimental chronic renal failure in the rat by ligation of the renal parenchyma. Nephron Exp Nephrol 2006;103:e126-e130.
23. Amann K, Irzyniec T, Mall G. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 1993;11:969-975.
24. Fleck C, Appenroth D, Jonas P, et al. Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats - influence of sex, strain, and surgical procedure. Exp Toxicol Pathol 2006; 57:195-205.
25. Imgrund M, Grone E, Grone HJ, et al. Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice 1. Kidney Int 1999;56:1423-1431.
26. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 2006;290:R861-R870.
27. Luria EA, Panasyuk AF, Friedenstein AY. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 1971;11:345-349.
28. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
29. Torrente Y, Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant 2008;17:1103-1113.
30. Ohnishi S, Ohgushi H, Kitamura S, et al. Mesenchymal stem cells for the treatment of heart failure. Int J Hematol 2007;86:17-21.
31. Popp FC, Piso P, Schlitt HJ, et al. Therapeutic potential of bone marrow stem cells for liver diseases. Curr Stem Cell Res Ther 2006;1:411-418.
32. Hofstetter CP, Schwarz EJ, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A 2002;99:2199-2204.
33. Weiss DJ, Kolls JK, Ortiz LA, et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5:637-667.
34. Caldas HC, Fernandes IM, Gerbi F, et al. Effect of whole bone marrow cell infusion in the progression of experimental chronic renal failure. Transplant Proc 2008;40:853-855.
35. Choi S, Park M, Kim J, et al. The role of mesenchymal stem cells in the functional improvement of the chronic renal failure. Stem Cells Dev 2009;18:521-529.
36. Asawa S, Saito T, Satoh A, et al. Participation of bone marrow cells in biliary fibrosis after bile duct ligation. J Gastroenterol Hepatol 2007;22:2001-2008.
37. Dunsmore SE, Shapiro SD. The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J Clin Invest 2004;113:180-182.
38. Lin SL, Kisseleva T, Brenner DA, et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008;173:1617-1627.
39. Haniffa MA, Collin MP, Buckley CD, et al. Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 2009;94:258-263.
40. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007;257:143-179.
41. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005;13:7-12.
42. Alexandre CS, Volpini RA, Shimizu MH, et al. Lineage-negative bone marrow cells protect against chronic renal failure. Stem Cells 2009;27:682-692.
43. Fujihara CK, Malheiros DM, Zatz R, et al. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54:1510-1519.
44. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease - are interventions possible? Nephrol Dial Transplant 2002;17:363-368.
45. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
46. Strutz FM. EMT and proteinuria as progression factors. Kidney Int 2009;75:475-481.
47. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007;117:3810-3820.
48. Inumaru J, Nagano O, Takahashi E, et al. Molecular mechanisms regulating dissociation of cell-cell junction of epithelial cells by oxidative stress. Genes Cells 2009 [Epub ahead of print].
49. Duffield JS, Park KM, Hsiao LL, et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest 2005;115:1743-1755.
50. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001;345:93-97.
51. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-525.
52. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
53. Li L, Zhang Y, Li Y, et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int 2008;21:1181-1189.
54. Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006;70:121-129.
55. Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 2004;65:409-419.
56. Gao X, Mae H, Ayabe N, et al. Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 2002;62:1238-1248.
57. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2003;284:F349-F357.
58. Kagawa T, Takemura G, Kosai K, et al. Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db/db mice. Nephron Physiol 2006;102:p92-p102.
59. Cruzado JM, Lloberas N, Torras J, et al. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004;53:1119-1127.
60. Camara NO, Soares MP. Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med 2005;38:426-435.
61. Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 2009;11:56-62.
62. Takahashi T, Shimizu H, Morimatsu H, et al. Heme oxygenase-1 is an essential cytoprotective component in oxidative tissue injury induced by hemorrhagic shock. J Clin Biochem Nutr 2009;44:28-40.